Oraxol

Phase 1Terminated

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Breastcancer

Conditions

Breastcancer

Trial Timeline

Oct 25, 2017 → Nov 12, 2020

NCT ID

NCT04168957

About Oraxol

Oraxol is a phase 1 stage product being developed by PharmaEssentia for Breastcancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04168957. Target conditions include Breastcancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04168957	Phase 1	Terminated	Oct 25, 2017	Nov 12, 2020	Breastcancer
NCT03165955	Phase 1	Completed	May 9, 2017	Nov 22, 2018	Breastcancer
NCT04180384	Phase 2	Completed	Sep 23, 2015	Jun 15, 2021	Solid Tumor

Competing Products

2 competing products in Breastcancer

See all competitors

Product	Company	Stage	Hype Score
Oraxol	PharmaEssentia	Phase 1	29
SV-BR-1-GM + Cyclophosphamide + Interferon-alpha-2b	BriaCell Therapeutics	Phase 1/2	22